<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561834</url>
  </required_header>
  <id_info>
    <org_study_id>07-0446</org_study_id>
    <secondary_id>genentech FVF4256s</secondary_id>
    <nct_id>NCT00561834</nct_id>
  </id_info>
  <brief_title>Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy</brief_title>
  <acronym>NAION</acronym>
  <official_title>Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (NAION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety and efficacy of ranibizumab to treat
      non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic
      neuropathy in people older than 50 years. It is characterized by sudden partial loss of
      vision in one eye and has an increased risk of vision loss in the fellow eye. Although cause
      has not been determined, NAION is thought to occur following an idiopathic ischemic event
      involving the short posterior ciliary arteries that supply blood to the most anterior part of
      the optic nerve. A complete loss of vision is rare, but partial loss of visual field or
      acuity can result from NAION in the affected eye(s).

      Patients who have a 'disc at risk' or 'crowded disc' (small cup: disc ratio) are at increased
      risk for developing NAION. Other risk factors for NAION include age &gt; 50 years and white race
      (estimated 95% of cases). Hypertension and diabetes also predispose to NAION development.
      Other factors that have been associated with NAION include high cholesterol,
      arteriosclerosis, stroke, cardiac and intraocular surgery, tobacco use, nocturnal
      hypotension, blood loss, glaucoma, elevated homocysteine and sleep apnea. The association
      between NAION and hypertension, high cholesterol and diabetes is stronger in individuals
      younger than 50 years than in older persons.

      Patients with NAION caused by ischemia leading to swelling of the optic nerve and rapidly
      progressing visual loss have had limited results with therapy such as corticosteroids,
      brimonidine, levodopa or surgery, such as optic nerve sheath decompression, in the past.
      Currently, there is no standard of care for these patients.

      Although the role of vascular endothelial growth factor (VEGF) in NAION has not been
      established, ischemic conditions may lead to VEGF production which could be the cause of
      edema and swelling. This possibility suggests that VEGF may be a target for therapeutic
      intervention by ranibizumab. Ranibizumab has demonstrated an effect on edema and vascular
      permeability. In animal studies it has shown a concentration- dependent effect of blunting
      the vascular permeability induced by VEGF. Of the more than 5,000 subjects with age-related
      macular degeneration in current and completed clinical trials, vascular permeability and
      edema have decreased with the use of ranibizumab.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Acuity</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The mean change in best corrected Snellen visual acuity at 6 months in NAION patients treated as needed with ranibizumab.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Nonarteritic Anterior Ischemic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the mean change in best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study testing system at 6 months in NAION patients treated as needed (PRN) with ranibizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.</description>
    <arm_group_label>Ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  provide written informed consent

          -  21 years of age or older

          -  new onset, within 14 days, of ischemia and vision loss

          -  Best Corrected Visual Acuity (BCVA) 20/40 or worse

        Exclusion Criteria:

          -  pregnancy or lactation

          -  proliferative diabetic retinopathy,

          -  diabetic macular edema,

          -  uveitis,

          -  history of ocular trauma,

          -  severe glaucoma,

          -  age-related macular degeneration.

          -  prior or concomitant treatment of oral steroids within 30 days,

          -  participation in any studies of investigational drugs within 30 days,

          -  participation in a ranibizumab clinical trial or,

          -  prior treatment intravitreally or intravenously of Avastin or steroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naresh Mandava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rocky Mountain Lions Eye Institute, University of Colorado Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Lions Eye Institute</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-0510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <results_first_submitted>March 3, 2014</results_first_submitted>
  <results_first_submitted_qc>June 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2016</results_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-arteritic ischemic optic neuropathy</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>naion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab</title>
          <description>ranibizumab: 0.5mg ranibizumab given intravitreally as needed after initial treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab</title>
          <description>ranibizumab: 0.5mg ranibizumab given intravitreally as needed after initial treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Acuity</title>
        <description>The mean change in best corrected Snellen visual acuity at 6 months in NAION patients treated as needed with ranibizumab.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab</title>
            <description>ranibizumab: 0.5mg ranibizumab given intravitreally as needed after initial treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity</title>
          <description>The mean change in best corrected Snellen visual acuity at 6 months in NAION patients treated as needed with ranibizumab.</description>
          <units>lines change in Snellen chart</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>lines change in visual acuity subject 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lines change in visual acuity -subject 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab</title>
          <description>ranibizumab: 0.5mg ranibizumab given intravitreally as needed after initial treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Naresh Mandava, M.D.</name_or_title>
      <organization>Rocky Mountain Lions Eye Institute, Dept. of Ophthalmology</organization>
      <phone>720-848-2500</phone>
      <email>Naresh.mandava@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

